Main articles (2020-2015)

Seledtsov VI, von Delwig A. Clinically feasible and prospective immunotherapeutic interventions in multidirectional comprehensive treatment of cancer. Expert Opin Biol Ther. 2020 Oct 3:1-20. doi: 10.1080/14712598.2021.1828338. Epub ahead of print. PMID: 32981358.

Seledtsov VI, Malashchenko VV, Meniailo ME, Atochin DN, Seledtsova GV, Schepetkin IA. Inhibitory effect of IQ-1S, a selective c-Jun N-terminal kinase (JNK) inhibitor, on phenotypical and cytokine-producing characteristics in human macrophages and T cells. Eur J Pharm. 2020; 2020 Jul 5; 878:173116. doi: 10.1016/j.ejphar

Seledtsov VI., von Delwig A.A. Immune memory limits human longevity: The role of memory СD4+ T cells in age-related immune abnormalities. Expert Rev Vac. 2020 Mar; 19(3):209-215. doi: 10.1080/14760584.2020.1745638..

Seledtsov VI, Malashchenko VV, Meniailo ME, Gazatova ND, Seledtsova GV. Granulocyte colony-stimulating factor downregulates interferon-gamma receptor expression and stimulates interleukin-6 production in activated human macrophages. Growth Factors. 2019 Aug; 37 (3-4):164-169. doi: 10.1080/08977194.2019.1662418.

Seledtsov VI., MalashchenkoV.V., Gazatova N.D., Meniailo ME., Morozova EM., Seledtsova GV. Directs effects of granulocyte-macrophage colony stimulating factor (GM-CSF) on adaptive immunogenesis. Human Vaccines & Immunotherapeutics. . 2019;15(12):2903-2909. doi: 10.1080/21645515.2019.1614396.

Seledtsov VI., Seledtsova GV. Total threshold cytotoxicity of therapeutic antibodies for selective destruction of pathogenic memory T cells: Implications for immunotherapy of autoimmune and allergenic disorders. Exp Rev Clin Immunol. 2019 Jul;15(7):701-706. doi: 10.1080/1744666X.2019.1617698.

Melashchenko O.V., Meniailo M.E., Malashchenko V.V., Gazatova N.D., Goncharov N.D., Seledtsova G.V., Seledtsov V.I. Erythropoietin-mediated modulation of human macrophage functionality. Current Pharmaceutical Biotechnology. 2018;19(11):902-9.

Seledtsov VI, Seledtsova GV. Attaining threshold antibody cytotoxicity for selective tumor cell destruction: an opinion article. Oncotarget. 2018; ;9(87):35790-4.

Meniailo ME, Malashchenko VV, Shmarov VA, Gazatova ND, Melashchenko OB, Goncharov AG, Seledtsova GV, Seledtsov VI. Interleukin-8 favors pro-inflammatory activity of human monocytes/macrophages. Int Immunopharmacol. 2018; 56:217-21.

Malashchenko VV, Meniailo ME, Shmarov VA, Gazatova ND, Melashchenko OB, Goncharov AG, Seledtsova G,V Seledtsov VI. Direct anti-inflammatory effects of granulocyte colony-stimulating factor (G-CSF) on activation and functional properties of human T cell subpopulations in vitro. Cell Immunol. 2018; 325:23-32.

Meniailo ME, Malashchenko VV, Shmarov VA, Gazatova ND, Melashchenko OB, Goncharov AG, Seledtsova G,V Seledtsov VI. Direct effects of interleukin-8 on growth and functional activity of T lymphocytes. Int Immunopharmacol. 2017; 50:178-85.

Seledtsov V.I., Seledtsova G.V. A possible role for idiotype/ anti-idiotype B—T cell interactions in maintaining immune memory. Front Immunol. 2017; 8:409. doi: 10.3389/fimmu.

Shmarov VA, Malashchenko VV, Meniailo ME, Gazatova ND, Todosenko NM, Melashchenko OB, Goncharov AG, Seledtsov VI. Direct effects of interleukin-7 on the functionality of human T cells in vitro. Eur Cytokine Netw. 2017; 27(4):102-7. doi: 10.1684/ecn.2016.0385.

Seledtsov V.I., Darinskas A., Seledtsova G.V. Xenogenic normal tissue-derived vaccines for breaking the immune tolerance to tumor-associated, antigens. Patent WO 2016046651 A1, 2016.

Seledtsova G.V.1, Irina P. Ivanova I.P., Shishkov А.А., Seledtsov V.I. Immune responses to polyclonal T-cell vaccination in patients with progressive multiple sclerosis. J Immunotox. 2016; 13(6):879-84.

Seledtsova G.V., Shishkov A.A., Kaschenko E.A, Seledtsov V.I. Xenonogeneic cell-based vaccine therapy for colorectal cancer: association of clinical effects with vaccine-induced immune responses. Biomed Pharmacother. 2016; 83: 1247-52.

Seledtsova G.V., Shishkov A.A., Kaschenko E. A.,. Goncharov A. G., Gazatova N. D., Seledtsov V.I. Xenonogeneic cell-based vaccine therapy for stage III melanoma: safety, immune-mediated responses and survival benefits. Eur J Dermat. 2016; 26: 138-43.

Todosenko NM, Shmarov VA, Malashchenko VV, Meniailo ME, Melashchenko OB, Gazatova ND, Goncharov AG, Seledtsov VI. Erythropoietin exerts direct immunomodulatory effects on the cytokine production by activated human T-lymphocytes. Int Immunopharmacol. 2016 ; 36: 277-81.

Atochin D.N., Schepetkin I.A., Khlebnikov A.I., Seledtsov V.I., Swanson H., Quinn M.T., Huang P.L. A novel dual NO-donating oxime and c-Jun N-terminal kinase inhibitor protects against cerebral ischemia—reperfusion injury in mice. Neurosci Lett. 2016; 618:45-9.

Seledtsov V.I., Goncharov A.G., Seledtsova G.V. Multiple-purpose immunotherapy for cancer. Biomedicine & Pharmacotherapy. 2015; 76: 24–9.

Seledtsov V.I., Goncharov A.G., Seledtsova G.V. Clinically feasible approaches to potentiating cancer cell-based immunotherapies. Human Vaccines & Immunotherapeutics.2015; 11(4):851-69.

Ivanova I.P, Seledtsova G.V., Mamaev S.V., Shishkov А.А., Seledtsov V.I. Immune responses induced by T-cell vaccination in patients with rheumatoid arthritis. Human Vaccines & Immunotherapeutics. 2014; 10(5):1221-7. doi: 10.4161/hv.28299.



Any other questions? Write to us